Alvotech to Raise $125M Through Equity Offering and Private Placement
ALVO sits 21% above its 52-week low of $2.94.
Summary
Alvotech announced a proposed $125 million public offering and concurrent private placement of ordinary shares. This capital raise is substantial, representing nearly 10% of the company's current market capitalization, and will likely result in significant dilution for existing shareholders. The company intends to use the net proceeds to fund the continued development of its biosimilar assets, working capital, and general corporate purposes. This financing follows recent mixed news, including a Q1 revenue decline and an adverse auditor opinion, alongside positive FDA acceptances for several biosimilar applications.
At the time of this announcement, ALVO was trading at $3.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.94 to $9.94. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.